Kimberly Rath, PharmD

Articles by Kimberly Rath, PharmD

Given the observed outcomes, camlipixant merits further study in severe RCC, especially among patients with a high initial cough burden. | Image credit: sebra - stock.adobe.com

A phase 2a trial of camlipixant, a selective P2X3 receptor antagonist, found that while the drug did not significantly reduce cough frequency in the overall population with refractory chronic cough, it produced meaningful improvements in patients with a higher baseline cough burden.

MDS graphic | Image Credit: © Sviatlana-stock.adobe.com

Findings from a phase 2 trial show that luspatercept effectively improves anemia in patients with lower-risk myelodysplastic syndromes (MDS), enabling them to delay or prevent transfusion dependence while maintaining a favorable safety profile.

Latest Updated Articles



Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo